RecruitingNCT05699096
Perfluorooctyl Bromide Which Empowers the Liquid to Flat the Detached Retina and Displace the Underneath Fluids Anteriorly
Perfluorooctyl Bromideessential for Repositioning Giant Retinal Breaks and Can be Used for Removal of Subretinal Fluid as Well as Stabilization of the Retina to Offset
Sponsor
EL Romany Ophthalmics Factory
Enrollment
20 participants
Start Date
Sep 1, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
Perfluorohexyloctaneis Essential for Repositioning Giant Retinal Breaks and Can be Used for Removal of Subretinal Fluid as Well as Stabilization of the Retina to Offset
Eligibility
Min Age: 20 YearsMax Age: 50 Years
Inclusion Criteria1
- \- Is 20 years or older Has been diagnosed with Keratoconus; Has no other active ocular disease; Is not pregnant or nursing;
Exclusion Criteria1
- Is under the age of 20 Has best corrected visual acuity outside 20/400; Pregnant or nursing at the time of enrollment in the study;
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05699096
Related Trials
Genotype-Phenotype Study of Patients With Plaquenil -Induced Retinal Toxicity, With Evaluation of the ABCA4 Gene
NCT011451961 location
Cell Collection to Study Eye Diseases
NCT014328471 location
COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Inherited Retinal Disease
NCT063800751 location
National Eye Institute Biorepository for Retinal Diseases
NCT014966251 location
Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
NCT0662717927 locations